Best Practice Using Rocuronium and Reversal With Neostigmine or Sugammadex
Muscle Weakness
About this trial
This is an interventional prevention trial for Muscle Weakness focused on measuring neostigmine, sugammadex, rocuronium, neuromuscular blocking agents
Eligibility Criteria
Inclusion Criteria: Adult 18 years old or older, Will undergo open or laparoscopic abdominal surgery or orthopedic surgery expected to last <6 hours at Harborview or Univ of Wash Med Ctr, Have American Society of Anesthesiologists physical status I-III, scheduled to have general anesthesia with at least 1 dose of nondepolarizing neuromuscular blocking drug for endotracheal intubation or intraoperative neuromuscular blockade.
-
Exclusion Criteria: Allergy to neuromuscular blocking drugs, patients with neuromuscular disease (myasthenia gravis or muscular dystrophy), pregnant or lactating women, non-English speaking.
-
Sites / Locations
- University of Washington Medical Center
Arms of the Study
Arm 1
Other
Subjects undergoing orthopedic or abdominal surgery
Subjects undergoing orthopedic or abdominal surgery requiring neuromuscular blockade. Subjects all receive the neuromuscular blockade drug Rocuronium based on study protocol. Depending on depth of block (subjectively assessed by TOF response), Neostigmine, Sugammadex, or no reversal drug is used to reverse block prior to extubation.